Really can stay in youth forever? The "young factor" in stem cells was found, and the main business of an A-share subsidiary was completely "right".
According to the Science and Technology Daily, Chinese scientists have first identified the presence of a “young factor”, multi-comb protein 4 (CBX4), in human mesenchymal stem cells, and verified its function. The relevant research results were published on the 26th. In the Cell Report. This may provide new ideas for the treatment of aging-related diseases.
According to reports, mesenchymal stem cells are one kind of stem cells, which are found in tissues such as bone marrow and epithelium. The research team's research shows that compared with young human mesenchymal stem cells, the expression of CBX4 in senescent cells is significantly reduced, suggesting that it plays a key role in the regulation of cell senescence.
In fact, China has intensified its support for stem cell research in recent years, and has also led to an endless stream of innovations. So far, there have been 4 batches of 35 stem cell clinical research projects in China that have been filed by the National Health and Health Commission and the Food and Drug Administration, including 7 clinical studies on stem cells such as Parkinson's disease, dry age-related macular degeneration, and meniscus injury. It is the most systematic clinical research carried out based on human embryonic stem cell differentiated cells in the world. Some projects have achieved certain stage results. The industry will also vigorously and continuously promote stem cell related projects in the Chinese Academy of Sciences to usher in a period of rapid development.
Related companies, according to the selected stock theme library (xuangubao.cn) precision medical sector shows:
Xiangxue Pharmaceutical: In August 2018, the company established a joint venture, Southern Precision Medicine Co., Ltd., focusing on precision medicine and systemic immunotherapy, conducting clinical research and application of gene diagnosis and specific cell therapy, and striving to create a hospital-based diagnosis of MDT disease. Therapeutic platform, systemic immunodiagnosis and treatment platform, stem cell research and treatment platform, health intervention and management platform.
Guanxi Biological: Together with Professor Deng Hongkui of Peking University, he established the Beibei Stem Cell and Regenerative Medicine Research Institute. Professor Deng Hongkui and the National Science and Technology Progress First Prize winner and Professor Chen Hu, Director of the Hematopoietic Stem Cell Transplantation Department of the People's Liberation Army 307 Hospital, successfully used gene editing technology. Modify the hematopoietic stem cell CCR5 gene to achieve anti-HIV virus effect in vivo.
International Medicine: Hans United, a 31%-owned subsidiary of the company, is a pioneer in the stem cell industry. Its main business covers placental stem cell collection and storage services, stem cell cosmetic anti-aging and stem cell drug development. It has established the world's first At the same time, the "stem cell bank" of the four placental tissue-derived stem cells is preserved.
评论
发表评论